Many psoriatic arthritis patients cycle through biologics, but few are truly refractory

Design

Multinational registry cohort, 1999–2020

Population

14,362 patients with psoriatic arthritis starting a first b/tsDMARD in 5 Nordic countries

Primary outcome

Prevalence of difficult-to-manage and treatment-refractory disease

Effect

≥2 discontinuations 36%; difficult-to-manage 2–3%; treatment-refractory 0.8–1.2%

This study used five Nordic biologics registries to follow 14,362 people with psoriatic arthritis starting their first biologic or targeted synthetic DMARD between 1999 and 2020, applying components inspired by the EULAR framework for difficult-to-manage and treatment-refractory disease.

Over a median 6.3 years, 36% stopped two or more of these drugs, 18% three or more, and 10% four or more. After adding criteria for reasons for stopping, multiple mechanisms, ongoing symptoms and objective disease activity, only 2–3% were difficult to manage and 0.8–1.2% treatment-refractory. Female sex, depression and opioid use became more common with each additional discontinuation.

Switching drugs often does not mean the inflammatory disease is resistant. Pain, depression, fibromyalgia-type symptoms and intolerance drive many switches. Before a fourth or fifth biologic, the question should be whether there is objective inflammation to treat.

• Check for objective inflammation — swollen joints, raised CRP, imaging — before switching another biologic
• Screen for depression and ask about opioid use in patients cycling through treatments
• Consider coexisting fibromyalgia or central pain when symptoms outstrip inflammatory markers
• Record the reason each drug was stopped to guide the next choice

Why it matters

Repeated drug switching often reflects problems a new biologic cannot fix.

Don't overread it

Registry-based approximations of the EULAR definitions — the study could not formally test them.

The statistics, in plain English

The registries could only approximate the EULAR definitions, so the prevalences are estimates. The associations with depression and opioid use are cross-sectional features, not causes.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.